Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/wmTnFbFcum

• https://buff.ly/jOLBrQY

Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV

• https://x.com/Janetbirdope/status/1933521871938412960/photo/1
• https://x.com/Janetbirdope/status/1933521871938412960/photo/1
• https://x.com/Janetbirdope/status/1933521871938412960/photo/1

PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity

Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj

In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m

• https://x.com/synovialjoints/status/1933527987514646938/photo/1

#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7

• https://x.com/Yuz6Yusof/status/1933532364443168839/photo/1

Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs? Greek cohort of SSc since 1995 Disease duration 12 yrs, smoking lung ca group ⬆️58% vs 29% ⬆️dcSSc ⬆️immunosuppression OR >4X lung ca if dcSSc, IS Less #DU #PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc

• https://x.com/Janetbirdope/status/1933461869336932504/photo/1
• https://x.com/Janetbirdope/status/1933461869336932504/photo/1

In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment? @RheumNow #EULAR2025 #OP0330

We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs: - lower inflamm - higher comorbidities Doesn’t necessarily map to fibromyalgia dx Beyond Rx, this is the critical question CareRA/2000 #EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb

• https://x.com/drdavidliew/status/1933465392296698091/photo/1
• https://x.com/drdavidliew/status/1933465392296698091/photo/1

Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025

High dose NSAIDs and incidence of HTN in axSpA? In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02). Interesting to

Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up? Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve

• https://x.com/drdavidliew/status/1933490836207251637/photo/1
• https://x.com/drdavidliew/status/1933490836207251637/photo/1

Maybe the pathogenesis gives us a clue on how to target things? Possibly the treatments which take down synovitis might not always help with nodules Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709

• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1
• https://x.com/drdavidliew/status/1933491474056032437/photo/1

#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr

• https://x.com/Yuz6Yusof/status/1933491657250410888/photo/1

#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ

• https://x.com/Yuz6Yusof/status/1933494060087492672/photo/1